Skip to main content
. Author manuscript; available in PMC: 2018 Feb 28.
Published in final edited form as: Nat Rev Urol. 2016 Oct 25;14(2):107–119. doi: 10.1038/nrurol.2016.199

Figure 1. Statin use, high cholesterol and prostate cancer deaths in the USA.

Figure 1

Age-adjusted US prostate cancer-specific mortality peaked in 1993 at 39 deaths per 100,000 men and has since been declining114. The percentage of US men ≥20 years of age with high total serum cholesterol (≥240 mg/dl per National Cholesterol Education Program guidelines115) has also declined, from 19% in 1987 to 12% in 2012(REFS 21,116). This reduction coincided with increasing prevalence of statin use (~26% of US adults ≥40 years of age in 2011–2012)2,116. Currently, seven statin drugs are being marketed in the USA. Lovastatin was the first agent to be approved by the FDA in 1987. The newest agent, pitavastatin, was approved in 2009. *Data of statin use before 2011–2012 relates to US adults aged ≥45 years116, data for 2011–2012 relates to US adults aged ≥40 years2.